Unichem Laboratories 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Pabitra Kumar Bhattacharya

최고 경영자

₹29.2m

총 보상

CEO 급여 비율	64.3%
CEO 임기	1.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	12.3yrs
이사회 평균 재임 기간	1.3yrs

최근 관리 업데이트

Recent updates

Revenues Tell The Story For Unichem Laboratories Limited (NSE:UNICHEMLAB) As Its Stock Soars 26%

Nov 02

It's A Story Of Risk Vs Reward With Unichem Laboratories Limited (NSE:UNICHEMLAB)

Sep 13

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Feb 06

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Jul 23

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 15

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 01

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Nov 27

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Jun 05

Should Unichem Laboratories Limited (NSE:UNICHEMLAB) Be Part Of Your Income Portfolio?

Mar 02

Unichem Laboratories Limited's (NSE:UNICHEMLAB) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?

Feb 09

Should You Take Comfort From Insider Transactions At Unichem Laboratories Limited (NSE:UNICHEMLAB)?

Jan 19

Do Institutions Own Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares?

Dec 29

Is Unichem Laboratories (NSE:UNICHEMLAB) Weighed On By Its Debt Load?

Dec 10

Key Things To Understand About Unichem Laboratories' (NSE:UNICHEMLAB) CEO Pay Cheque

Nov 23

Did Unichem Laboratories' (NSE:UNICHEMLAB) Share Price Deserve to Gain 41%?

Nov 02

Should You Buy Unichem Laboratories Limited (NSE:UNICHEMLAB) For Its 1.5% Dividend?

Oct 13

How Much Are Unichem Laboratories Limited (NSE:UNICHEMLAB) Insiders Spending On Buying Shares?

Sep 16

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Too Much Debt?

Aug 26

Is Unichem Laboratories Limited's (NSE:UNICHEMLAB) Shareholder Ownership Skewed Towards Insiders?

Aug 05

Would Shareholders Who Purchased Unichem Laboratories'(NSE:UNICHEMLAB) Stock Three Years Be Happy With The Share price Today?

Jul 14

CEO 보상 분석

Pabitra Kumar Bhattacharya 의 보수는 Unichem Laboratories 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-₹56m
Jun 30 2024	n/a	n/a	-₹606m
Mar 31 2024	₹29m	₹19m	-₹705m

보상 대 시장: Pabitra Kumar 의 총 보상 ($USD 345.49K )은 Indian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 355.26K ).

보상과 수익: Pabitra Kumar 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Pabitra Kumar Bhattacharya (55 yo)

1.3yrs

테뉴어

₹29,175,000

보상

Mr. Pabitra Kumar Kalipada Bhattacharya had been Managing Director of Krebs Biochemicals & Industries Limited since August 1, 2021 until August 9, 2023 and had been its Additional Director since July 30, 2...

리더십 팀

이름	위치	테뉴어	보상	소유권
Pabitra Kumar Bhattacharya	MD & Director	1.3yrs	₹29.18m	데이터 없음
Pradeep Bhandari	Head of Legal	5.3yrs	₹9.84m	데이터 없음
Dhananjay Sathe	Chief Scientific & Compliance Officer	no data	데이터 없음	데이터 없음
Prasad Joshi	Vice President of Human Resources & ER	16.4yrs	₹7.48m	데이터 없음
Vinod Behl	Head of Projects & Investments	no data	₹2.10m	데이터 없음
Jalesh Burye	Chief Quality & Compliance Officer	no data	데이터 없음	데이터 없음
Ashwani Kumar	Chief Manufacturing & Compliance Officer	no data	데이터 없음	데이터 없음
Bhagwat Dhingra	Chief Executive of Domestic Pharma	12.3yrs	₹13.62m	데이터 없음
Scott Delaney	President of North America & CEO of North America	6.4yrs	데이터 없음	데이터 없음
P. Deshpande	Vice President of Chemical of Research and Development	no data	₹593.35k	데이터 없음
Gajendra Ghanekar	Vice President of Commercial	24yrs	₹6.14m	데이터 없음
R. Shapeti	Advisor of Active Pharmaceutical Ingredients (API)	no data	₹5.24m	데이터 없음

12.3yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 관리: UNICHEMLAB 의 관리팀은 노련하고 경험 (평균 재직 기간 12.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Pabitra Kumar Bhattacharya	MD & Director	1.3yrs	₹29.18m	데이터 없음
Prakash Mody	Chairman	50.4yrs	₹328.40m	16.21% ₹ 9.8b
Arun Todarwal	Independent Director	less than a year	₹100.00k	데이터 없음
Pranay Godha	Non-Executive Non-Independent Director	1.3yrs	₹300.00k	데이터 없음
Priti Puri	Additional Independent Non-Executive Director	1.7yrs	₹850.00k	데이터 없음
Anand Kusre	Independent Director	less than a year	₹100.00k	데이터 없음

1.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: UNICHEMLAB 의 이사회는 경험(평균 재직 기간 1.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Unichem Laboratories 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

High number of new directors

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Recent updates

Second quarter 2025 earnings released: EPS: ₹4.34 (vs ₹3.48 loss in 2Q 2024)

Revenues Tell The Story For Unichem Laboratories Limited (NSE:UNICHEMLAB) As Its Stock Soars 26%

Unichem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024

It's A Story Of Risk Vs Reward With Unichem Laboratories Limited (NSE:UNICHEMLAB)

Unichem Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024

High number of new directors

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

New major risk - Revenue and earnings growth

Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Debt Sensibly?

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Does Unichem Laboratories (NSE:UNICHEMLAB) Have A Healthy Balance Sheet?

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Unichem Laboratories (NSE:UNICHEMLAB) Is Due To Pay A Dividend Of ₹4.00

Upcoming dividend of ₹4.00 per share

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration

Should Unichem Laboratories Limited (NSE:UNICHEMLAB) Be Part Of Your Income Portfolio?

New 90-day high: ₹332

Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited's (NSE:UNICHEMLAB) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?

New 90-day high: ₹295

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020)

Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA